Monthly cholecalciferol administration in haemodialysis patients: A simple and efficient strategy for vitamin D supplementation

Nephrology Dialysis Transplantation

Volumn 24, Issue 12, 2009, Pages 3799-3805

  Jean, Guillaume ^a   Souberbielle, Jean Claude ^b   Chazot, Charles ^a  

^a Centre de Rein Artificiel de Tassin   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cholecalciferol; Haemodialysis; Mineral metabolism; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CINACALCET; COLECALCIFEROL; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; SERUM ALBUMIN; UNCLASSIFIED DRUG; UVEDOSE; VITAMIN D DERIVATIVE;

ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH CARE COST; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ADMINISTRATION, ORAL; AGED; CHOLECALCIFEROL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS; VITAMIN D DEFICIENCY; VITAMINS;

EID: 71049186478     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp370     Document Type: Article

References (44)

1. Heaney RP. Vitamin D in health and disease. Clin J Am Soc Nephrol 2008; 3: 1535-1541
2. Chapuy MC, Arlot ME, Duboeuf F et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992; 327: 1637-1642
3. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281
4. Zittermann A, Schleithoff SS, Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 2005; 94: 483-492
5. Visser M, Deeg DJH, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003; 88: 5766-5772
6. Jean G, Charra B, Chazot C. Vitamin D deficiency and associated factors in hemodialysis patients. J Ren Nutr 2008; 18: 395-399
7. Saab G, Young DO, Gincherman Y et al. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 2007; 105: c132-c138
8. Dawson-Hughes B, Heaney RP, Holick MF et al. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16: 713-716
9. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: 1-201
10. Coen G, Mantella D, Manni M et al. 25-hydroxyvitamin D levels and bone histomorphometryin hemodialysis renal osteodystrophy.Kidney Int 2005; 68: 1840-1848
11. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013
12. Jean G, Terrat JC, Vanel T et al. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Nephron Clin Pract 2008; 110: c58-c65
13. Lambert PW, Stern PH, Avioli RC et al. Evidence for extrarenal production of 1 alpha,25-dihydroxyvitamin D in man. J Clin Invest 1982; 69: 722-725
14. Dusso A, Finch J, Delmez J et al. Extrarenal production of calcitriol. Kidney Int Suppl 1990; 29: S36-S40
15. Tokmak F, Quack I, Schieren G et al. High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant 2008; 23: 4016-4020
16. Jean G,Terrat J-C, Vanel Tet al. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant 2008; 23: 3670-3676
17. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005; 135: 317-322
18. Maghbooli Z, Hossein-NezhadA,Karimi Fet al. Correlation between vitamin D3 deficiency and insulin resistance in pregnancy. Diabetes Metab Res Rev 2008; 24: 27-32
19. Del Valle E, Negri AL, Aguirre C et al. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int 2007; 11: 315-321
20. Perwad F, Zhang MY, Tenenhouse HS et al. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007; 293: F1577-F1583
21. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-F28
22. Usatii M, Rousseau L, Demers C et al. Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)2D synthesis. Kidney Int 2007; 72: 1330-1335
23. Ghazali A, Fardellone P, Pruna A et al. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int 1999; 55: 2169-2177
24. Jones G. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3). Semin Dial 2007; 20: 316-324
25. Wintergerst ES, Maggini S, Hornig DH. Contribution of selected vitamins and trace elements to immune function. Ann Nutr Metab 2007; 51: 301-323
26. London GM, Guerin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620
27. Gurlek A, Pittelkow MR, Kumar R. Modulation of growth fac-tor/cytokine synthesis and signaling by 1alpha,25-dihydroxyvitamin D(3): implications in cell growth and differentiation. Endocr Rev 2002; 23: 763-786
28. Hewison M, Burke F, Evans KN et al. Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease. J Steroid Biochem Mol Biol 2007; 103: 316-321
29. Ritter CS, Armbrecht HJ, Slatopolsky E et al. 25-Hydroxyvitamin D3 suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 2006; 70: 654-659
30. Adams JS, Clemens TL, Parrish JA et al. Vitamin-D synthesis and metabolism after ultraviolet irradiation of normal and vitamin-D-deficient subjects. N Engl J Med 1982; 306: 722-725
31. Hathcock JN, Shao A, Vieth R et al. Risk assessment for vitamin D. Am J Clin Nutr 2007; 85: 6-18
32. Holick MF, Biancuzzo RM, Chen TC et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008; 93: 677-681
33. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004; 89: 5387-5391
34. Chandra P, Binongo JN, Ziegler TR et al.Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract 2008; 14: 10-17
35. Tokmak F, Quack I, Schieren G et al. High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant 2008; 23: 4016-4020
36. Courbebaisse M,Thervet E, Souberbielle JCet al. Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int 2008; 75: 646-651
37. Ilahi M, Armas LA, Heaney RP. Pharmacokinetics of a single, large dose of cholecalciferol. Am J Clin Nutr 2008; 87: 688-691
38. Khaw KT, Scragg R, Murphy S. Single-dose cholecalciferol suppresses the winter increase in parathyroid hormone concentrations in healthy older men and women: a randomized trial. Am J Clin Nutr 1994; 59: 1040-1044
39. Halloran BP, Schaefer P, Lifschitz M et al. Plasma vitamin D metabolite concentrations in chronic renal failure: effect of oral administration of 25-hydroxyvitamin D3. J Clin Endocrinol Metab 1984; 59: 1063-1069
40. Slatopolsky E, Weerts C, Thielan J et al. Marked suppression of secondary hyperparathyroidismbyintravenous administrationof1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143
41. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456 (Pubitemid 36910023)
42. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187
43. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodial-ysis patients. Kidney Int 2006; 70: 771-780
44. Chel V, Wijnhoven HA, Smit JH et al. Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents. Osteoporos Int 2008; 19: 663-671